Navigation Links
Cadence Pharmaceuticals Comments on USPTO's Non-Final, Initial Office Action on Reexamination of Patent
Date:8/15/2013

patent are appropriate and that the USPTO's prior issuance of the patent was correct, the company's plans to continue the reexamination and file additional claims, and Cadence's ability to make a strong case in favor of the patentability of the rejected claims. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Cadence's actual future results may differ materially from the company's current expectations due to the risks and uncertainties inherent in its business. These risks include, but are not limited to: Cadence's dependence on the successful commercialization of OFIRMEV, which is the company's only product; Cadence's ability to achieve broad market acceptance and generate revenues from sales of OFIRMEV; Cadence's ability to successfully enforce its marketing exclusivities and intellectual property rights, and to defend the patents covering OFIRMEV, including in current intellectual property litigation with the parties that have submitted new drug applications ("NDAs") or abbreviated new drug applications ("ANDAs") for generic versions of OFIRMEV; the potential that Cadence may be required to continue intellectual property litigation for substantial lengths of time or file additional lawsuits to defend its patent rights from challenges by companies that have submitted NDAs or ANDAs for generic versions of OFIRMEV, and the substantial costs associated with such lawsuits; the potential introduction of generic competition to OFIRMEV in the event Cadence is unsuccessful in current or future intellectual property litigation, and the impact it may have on the sales and pricing of the product; Cadence's dependence on its licensors for the maintenance and enforcement of its intellectual property rights; the potential product liability exposure associated with pharmaceutical products such as OFIRMEV and other products Cadence may in-license or acquire; Cadence's ability to fully comply with numerous f
'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cadence Pharmaceuticals Appoints Laureen DeBuono to its Board of Directors
2. Cadence Pharmaceuticals To Present At The 2013 Wedbush PacGrow Life Sciences Management Access Conference On August 13, 2013
3. Cadence Pharmaceuticals Reports Second Quarter 2013 Financial Results
4. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Second Quarter 2013 Financial Results On July 31, 2013
5. Cadence Pharmaceuticals To Present At Three Investment Conferences During The Month Of May 2013
6. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss First Quarter 2013 Financial Results On May 2, 2013
7. Cadence Pharmaceuticals Appoints Stephen L. Newman, M.D., to its Board of Directors
8. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results
9. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Fourth Quarter And Full Year 2012 Financial Results On March 7, 2013
10. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Cowen & Company 33rd Annual Health Care Conference In Boston On March 5, 2013
11. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Leerink Swann Global Healthcare Conference In New York City On February 13, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 22, 2015  The U.S. Food and Drug ... the first biosimilar product approved in ... growth in the contract manufacturing organization (CMO) industry, ... is geared to the production of small-molecular drugs ... products. The healthcare market research publisher,s report, ...
(Date:5/22/2015)... 20, 2015 Research and Markets( http://www.researchandmarkets.com/research/28m7nx/guide_to_prepare ... "Guide to Prepare Application Dossiers for Oversea Medical ... " report to their offering. ... segment market of the most growth potentiality, which ... manufacturers and producers to penetrate such market. It ...
(Date:5/22/2015)... 22, 2015 Richmond Pharmacology ... unit with a worldwide reputation for excellence in ... publications in peer reviewed medical journals. Its officers ... regulators in discussions about rules for transparency and ... (Logo: http://photos.prnewswire.com/prnh/20150522/745125) , Clinical research is ...
Breaking Medicine Technology:Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 2China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 3
... - Arrowhead,Research Corporation (NASDAQ:ARWR) announced today that,majority-owned ... Proceedings of the National Academy of Sciences,(PNAS) ... use multiple,systemic dosing with Calando's lead siRNA ... technologies in targeted,polymeric delivery systems and siRNA ...
... in Two Most Common Mutations, CRANBURY, N.J., ... biopharmaceutical company developing small,molecule, orally-administered pharmacological chaperones ... genetic diseases, announced today,that it will present ... tartrate, AT2101) for Gaucher disease at,the of ...
Cached Medicine Technology:Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on,Targeted, Systemic Delivery of siRNA 2Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on,Targeted, Systemic Delivery of siRNA 3Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease 2Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease 3
(Date:5/22/2015)... 2015 Mountain Point Medical Center, a campus ... ceremony on Friday, May 29, 2015 at 11 a.m., followed ... The new medical center, set to officially open on June ... UT 84043. , “The opening of Mountain Point Medical ... Utah County community,” said Kent Loosle, CEO of Mountain Point ...
(Date:5/22/2015)... 2015 Combination therapy, or polytherapy, ... chronic obstructive pulmonary disorder (COPD) as the dominant ... plc as well as Germany’s Boehringer Ingelheim compete ... But will market payers, clinicians and patients be ... to completely new ones? , In spite of ...
(Date:5/22/2015)... Coordinating care for people with ... providers have not been reimbursed or rewarded for ... Medicare has paved the way by offering reimbursement ... launch of Oculus Health , an innovative ... the platform will now be able to easily ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 ... Health IT solutions, announced today that Bill Lane, ... is the developer of BlueEHS,a first of its ... offers a customizable Electronic Health Records (EHR) with ... interfaces, a telemedicine-enabled comprehensive patient portal, and more. ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 sweetFrog Enterprises, LLC. ... in Jacksonville, Texas. Jacksonville is now the 16th sweetFrog store ... chain was listed as #22 on the Inc. 500 list ... have lived and worked in East Texas for 20 years ... Anderson, owner of the Jacksonville, and nearby Palestine, sweetFrog locations. ...
Breaking Medicine News(10 mins):Health News:Mountain Point Medical Center, a Campus of Jordan Valley Medical Center, Hosts Ribbon Cutting Ceremony and Community Celebration on Friday, May 29, 2015 2Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Oculus Health Care Coordination Platform Officially Launched 2Health News:Oculus Health Care Coordination Platform Officially Launched 3Health News:Oculus Health Care Coordination Platform Officially Launched 4Health News:ZH Healthcare Adds Bill Lane to Advisory Board 2Health News:sweetFrog Opens New Location in Jacksonville, Texas 2
... prevention or delay of full-blown disease seen in treated ... Among patients who show early signs of multiple sclerosis, ... halve the risk that they will develop full-blown disease, ... who are diagnosed with multiple sclerosis first show signs ...
... With the thermometer dropping and the onset of flu ... and the public to encourage them to get a seasonal ... supported healthy behaviors and prevention efforts," said Merri Dee, AARP ... protect themselves and those around them by getting vaccinated." , ...
... $30 billion and $34 billion reside in the asbestos ... to pay claims brought by workers who contracted asbestos-related ... Asbestos Litigation Conference" produced in San Francisco by HB ... state court judges from around the country who shared ...
... WASHINGTON, Pa., Oct. 6 RAM Technologies, Inc., ... for health plans, has once again been named ... Tech Employers in the Greater Philadelphia region. ... edge applications that automate the administration of health ...
... While little is known about the causes of glioma, ... this rare but often deadly form of brain cancer ... height. "Our findings suggest that biological factors ... play a role in glioma etiology. This clue could ...
... ... 2009 News Briefs are designed to keep you up-to-date on embargoed studies ... Society of Plastic Surgeons (ASPS) held October 23-27 in Seattle. All briefs ... advance copy of study abstracts, for media registration, or to arrange interviews ...
Cached Medicine News:Health News:Early Drug Treatment May Cut Multiple Sclerosis Risk 2Health News:AARP Encourages All Adults 50+ to Get Flu Vaccine This Season 2Health News:Asbestos Trusts, Asbestos Judges Featured at Two HB Events Dec. 2 & 3 2Health News:RAM Technologies Named to Philadelphia Business Journal's List of Top Tech Employers 2Health News:Physical activity in adolescence associated with decreased risk of brain cancer in adulthood 2Health News:Physical activity in adolescence associated with decreased risk of brain cancer in adulthood 3Health News:Plastic Surgery 2009 News Briefs - Select Research to be Presented on Sunday, October 25 2Health News:Plastic Surgery 2009 News Briefs - Select Research to be Presented on Sunday, October 25 3Health News:Plastic Surgery 2009 News Briefs - Select Research to be Presented on Sunday, October 25 4Health News:Plastic Surgery 2009 News Briefs - Select Research to be Presented on Sunday, October 25 5Health News:Plastic Surgery 2009 News Briefs - Select Research to be Presented on Sunday, October 25 6
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: